Remote Ischemic Preconditioning to Prevent Early Worsening After a Small-Vessel Stroke
Tests remote ischemic preconditioning to prevent early worsening in adults with acute perforating artery stroke.
Plain-language title generated from the registry record
Registry title: Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction
Key facts
- Where
- Nanjing, ChinaSee the site
Where in China
- Jinling Hospital, Medical School of Nanjing University, NanjingNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jinling Hospital, China
- Trial code
- NCT07237542
- Record updated
- 3 February 2026
- Original description
This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).Read full original descriptionShow less
Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction (RIC-END): A Randomised Multicentre Trial
This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).
Inclusion: Age 18 years or older; Diagnosed with acute ischemic stroke; Clinical symptoms consistent with perforating artery infarction (NIHSS score ≤5, with consciousness item 1a ≤1); Time from onset to randomization within 48 hours; Diffusion-weighted imaging (DWI) showing a single infarct in the perforating artery territory with a maximum diameter ≤30 mm, meeting at least one of the following:; (1) Diameter ≤15 mm and involving two or more axial slices; (2) Maximum diameter ≥15 mm; (3) Connected to the ventral surface of the pons but not crossing the midline; 6) Stenosis of parent artery <70%; 7) Signed informed consent obtained from the patient or their legally authorized representative.
Exclusion: Received intravenous thrombolysis or endovascular treatment prior to randomization; Secondary stroke caused by brain tumor, traumatic brain injury, hematologic disorders, or other conditions; History of intracranial hemorrhage; Presence of RIC contraindications, such as severe upper limb soft tissue injury, fracture, subclavian artery stenosis, or peripheral vascular disease; Uncontrolled severe hypertension (systolic blood pressure [BP] ≥180 mmHg or diastolic BP ≥110 mmHg); Patients with thrombocytopenic purpura, coagulation disorders, or active visceral bleeding; Patients in the acute phase of fundus hemorrhage; History of severe aphasia or psychiatric disorders affecting clinical assessment; Severe hepatic or renal dysfunction (Alanine Aminotransferase or Aspartate Aminotransferase > 3 × upper limit of normal; creatine kinase >3 × upper limit of normal; estimated Glomerular Filtration Rate < 30 mL / min / 1.73 m²); Life expectancy <90 days; Pregnancy; Inability to comply with follow-up; Participation in other clinical trials.